(Q33723420)

28 July 2017

1 reference

title

T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis (English)

1 reference

28 July 2017

1 reference

Yocum DE

1

1 reference

28 July 2017

publication date

1 August 1999

1 reference

Seminars in Arthritis and Rheumatism

28 July 2017

published in

1 reference

28 July 2017

volume

29

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

27-35

1 reference

Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Genetic susceptibility to rheumatoid arthritis and human leukocyte antigen class II polymorphism. The role of shared conformational determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Specificity of the proteus antibody response in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Hypothesis for retroviral causation of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis. Evidence of restricted IgG3 subclass expression and activation of complement C5 to C5a

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Cross-reactivity between the EBNA-1 p107 peptide, collagen, and keratin: Implications for the pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Immunoelectron microscopic study of the distribution of T cell subsets in rheumatoid synovium

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Collagen arthritis in the rat is initiated by CD4+ T cells and can be amplified by iron

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

The induction of arthritis in mice by the cartilage proteoglycan aggrecan: roles of CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Lack of association of T cell receptor V beta 8 polymorphism with rheumatoid arthritis in United Kingdom and Italian white patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Lack of T cell oligoclonality in enzyme-digested synovial tissue and in synovial fluid in most patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Dominant T-cell-receptor beta chain variable region V beta 14+ clones in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

T cell receptor V beta gene bias in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Biologic agents for treating rheumatoid arthritis. Concepts and progress

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

DAB486IL-2 fusion toxin in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

The mechanism of action of FK-506 and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2899%2980035-3

7 January 2021

10.1016/S0049-0172(99)80035-3

Identifiers

DOI

1 reference

28 July 2017

1 reference